Gene · 432
Papers2,727
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,727
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The emerging role of glycans and the importance of sialylation in cardiovascular disease. | Atherosclerosis | 2025 | 40138819 | PubTator, text mining | PubMed |
| Enhanced Photosensitizer-Embedded Glycopolymers through Self-Catalytic PET-RAFT Polymerization for Targeted PDT. | Biomacromolecules | 2025 | 40128096 | PubTator, text mining | PubMed |
| Discovery of ASGR1 and HMGCR dual-target inhibitors based on supervised learning, molecular docking, molecular dynamics simulations, and biological evaluation. | Bioorg Chem | 2025 | 40080975 | PubTator, text mining | PubMed |
| Advancement of drugs conjugated with GalNAc in the targeted delivery to hepatocytes based on asialoglycoprotein receptor. | Carbohydr Res | 2025 | 40068307 | PubTator, text mining | PubMed |
| Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. | Signal Transduct Target Ther | 2025 | 40059188 | PubTator, text mining | PubMed |
| Trivalent siRNA-Conjugates with Guanosine as ASGPR-Binder Show Potent Knock-Down In Vivo. | J Med Chem | 2025 | 40052708 | PubTator, text mining | PubMed |
| Serum Soluble Asialoglycoprotein Receptor 1: A Potential Predictor Marker Linked to Type 2 Diabetes Mellitus, Demonstrating Positive Correlation With High Sensitive C-Reactive Protein. | Diabetes Metab Syndr Obes | 2025 | 40046108 | PubTator, text mining | PubMed |
| On the interaction of anticancer G-quadruplex ligands with GalNAc-functionalized G-quadruplex-forming carriers for selective recognition and treatment of hepatocellular carcinoma. | Bioorg Chem | 2025 | 40015110 | PubTator, text mining | PubMed |
| Plasma proteins and herpes simplex virus infection: a proteome-wide Mendelian randomization study. | Virus Genes | 2025 | 39992613 | PubTator, text mining | PubMed |
| Association Analysis of the Circulating Proteome With Sarcopenia-Related Traits Reveals Potential Drug Targets for Sarcopenia. | J Cachexia Sarcopenia Muscle | 2025 | 39949133 | PubTator, text mining | PubMed |
| GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases. | Expert Opin Drug Deliv | 2025 | 39939158 | PubTator, text mining | PubMed |
| Small Extracellular Vesicles Engineered Using Click Chemistry to Express Chimeric Antigen Receptors Show Enhanced Efficacy in Acute Liver Failure. | J Extracell Vesicles | 2025 | 39901768 | PubTator, text mining | PubMed |
| Fusarolides A-C, Three Pyran-Macrolide Hybrids from a Marine Derived Fungal Fusarium verticillioide G102 as Asialoglycoprotein receptor 1 Inhibitor and Phytopathogenic Fungicides. | Org Lett | 2025 | 39895130 | PubTator, text mining | PubMed |
| Whole-Body Physiologically Based Pharmacokinetic Modeling of GalNAc-Conjugated siRNAs. | Pharmaceutics | 2025 | 39861717 | PubTator, text mining | PubMed |
| Integrated SegFlow, µSIA, and UPLC for Online Sialic Acid Quantitation of Glycoproteins Directly from Bioreactors. | Eng Life Sci | 2025 | 39850488 | PubTator, text mining | PubMed |
| An ASGP-R-targeting magnetic resonance imaging contrast agent for liver cancer diagnosis. | J Mater Chem B | 2025 | 39838934 | PubTator, text mining | PubMed |
| Recent advances in self-targeting natural product-based nanomedicines. | J Nanobiotechnology | 2025 | 39833846 | PubTator, text mining | PubMed |
| Anticancer efficacy of thiazole-naphthyl derivatives targeting DNA: Synthesis, crystal structure, density functional theory, molecular docking, and molecular dynamics studies. | Int J Biol Macromol | 2025 | 39828180 | PubTator, text mining | PubMed |
| Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics. | Chem Rev | 2025 | 39818743 | PubTator, text mining | PubMed |
| Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D. | J Virol | 2025 | 39791910 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/432/papers?page=9